Login to Your Account

No ‘weight’-ing: Celgene’s Otezla wins FDA nod on PDUFA date

By Randy Osborne
Staff Writer

Friday, March 21, 2014
Right on time, the FDA approved Celgene Corp.’s phosphodieasterase-4 inhibitor Otezla (apremilast) for adults with active psoriatic arthritis (PsA), a drug that could sell in the range of $1.5 billion to $2 billion by 2017, the company said.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription